Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 236-671-3 | CAS number: 13463-41-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Carcinogenicity
Administrative data
Description of key information
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 0.5 mg/kg bw/day
Justification for classification or non-classification
Additional information
The information contained within this robust summary document comes from studies which are in the ownership of Arch Chemicals Inc. and which are protected in several regions globally. This information may not be used for any purpose other than in support of the Chemical safety Report submitted by Arch Chemicals Inc. under RegulationEC 1907/2006.
Available studies are presented in Tables 5.12 and 5.13 below. Studies have been carried out in the rat and the mouse. Further studies were not carried out in dogs because of the known effect of Pyrithiones on the tapetum of the dog which results in blindness in the dog, seeDelahunt, C.S., Stebbins, R.B., Anderson, J., and Bailey, J. (1962).andCloyd, G.G., Wyman, M., Shadduck, JA. (1978).
In an old and shortly reported non-guideline study with rat,Larson (1958), Zinc pyrithione had no carcinogenic potential to rat with the used doses.
Nonetheless, in studies with Sodium Omadine, with oral sampling with rat and dermal sampling with mouse, also no evidence of tumourigenic potential was identified.
A GLP study to GuidelineUS EPA 83-2, which complies with OECD 453.byHusband (1991),investigated the oral (gavage) administration of Sodium Pyrithione to rats over 104 weeks. This study constituted a combined carcinogenicity / chronic toxicity study.
An NOEL of 0.5 mg/kg bw/day was established in the study.
A GLP study to GuidelineUS EPA 83-2, which complies with OECD 453.byHusband (1991), investigated the DERMAL oral (gavage) administration of Sodium Pyrithione to the mouse over 80 weeks. This study constituted a combined carcinogenicity / chronic toxicity study.
An NOEL of 0.5 mg/kg bw/day was established in the study.
A GLP study to GuidelineUS EPA OPPTS 870.4300 which complies with OCED 453,byCivalese et al (2004),investigated the oral (gavage) administration of sodium pyrithione to rats over 104 weeks. This study constituted a combined carcinogenicity / chronic toxicity study.
An NOAEL for both sexes can be considered to be 0.5 mg/kg/day.
In a non-GLP study conducted byLarson (1958),60 male and 60 female rats were exposed to zinc pyrithione in the diet at 0, 2, 5, 10, 25, and 50 ppm for 2 years.
The NOAEL for this study was 10 ppm (0.5 mg/kg/day)based on a reduced survivability in female animals at 25 ppm and hind limb weakness at 25 and 50 ppm. Male rats were observed to have a decrease in body weight at 50 ppm.
1.1.1.1 Carcinogenicity: oral
Table 5.12: Summary of carcinogenicity via the oral route
Method |
Results |
Remarks |
Reference |
US EPA 83-2, which complies with OECD 453. GLP Oral(gavage) Rat Crl: CD (SD) (VAF Plus) 50 per sex per dose. 0, 0.5, 1.5 and 3.5 mg/kg bw/day Duration: 2 years |
LO(A)EL – 1.5 mg/kg bw/day NO(A)EL – 0.5 mg/kg bw/day Sodium Omadine did not affect tumour formation adversely. Decreases in body weight gain, hind limb muscle atrophy and histopathological changes in skeletal muscle, spinal cord and in the eyes were observed in the high dose group. Some, but not all of these effects were observed to a lesser degree in the mid dose group. |
Reliability – 1 Purpose flag Study result type Test material: Sodium Omadine, 41.2% aqueous dispersion |
Husband RFA, Newman AJ and Lee PN (1991) (unpublished) |
US EPA 83-2, which complies with OECD 453. GLP Oral(gavage) Rat Duration: 2 years
|
NO(A)EL – 0.5 mg/kg bw/day Signs of toxicity, such as, ataxia, decreased muscle tone and emaciation were seen in animals of both sexes. In addition, a lower body weight was noted in low and high-dose males and in mid- and high- dose females when compared to controls. There were no incidences of neoplasia with sodium pyrithione up to 2.8 mg/kg/day.
|
Reliability – 1 Purpose flag Study result type Test material: Sodium Pyrithione |
Key study Cicalese R, Argentino-Storino A, (2004) (unpublished) |
No specific guideline. Oral, Rat strain not stated 10 per sex per dose.0, 2, 5, 10, 25 and 50 ppm in diet (about 0.2, 0.5, 1.0, 2.5 and 5.0 mg/kg bw/day)
Duration: 2 years
|
LO(A)EL – Females 25 ppm Males 50 ppm NO(A)EL – 10 ppm (0.5 mg/kg/day) In male rats, no effects were noted on survival, whereas in female rats with 25 and 50 ppm diets, numbers of survived animals decreased. Death was commonly preceded by the development of hind limb paralysis. |
Reliability – 1 Purpose flag Study result type Test material: Zn Pyrithione, purity not stated. |
Larson PS (1958) (unpublished) |
1.1.1.2 Carcinogenicity: inhalation
This information is not available.
1.1.1.3 Carcinogenicity: dermal
Table 5.13: Summary of carcinogenicity via the dermal route
Method |
Results |
Remarks |
Reference |
US EPA 83-2, which complies with OECD 453. GLP Dermal, Mouse Crl: CD-1 (ICR) BR (VAF Plus) 50 per sex per dose.0, 5, 15 and 40 mg/kg bw/day Duration: 80 weeks |
LO(A)EL - 15 mg/kg bw/day NO(A)EL – 5 mg/kg bw/day Sodium Omadine did not affect tumour formation adversely. The only observed lesion, which appeared to be related to the treatment, was epidermal hyperplasia at the application sites of high and mid dose animals. |
Reliability – 1 Purpose flag Study result type Test material: Sodium pyrithione 41.2% aqueous dispersion. |
Husband RFA, Newman AJ and Lee PN (1991) (unpublished) |
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.